Echinacoside suppresses dexamethasone‑induced growth inhibition and apoptosis in osteoblastic MC3T3‑E1 cells

Li,Sibo; Jiang,Haitao; Gu,Xiaohua

doi:10.3892/etm.2018.6199

Echinacoside suppresses dexamethasone‑induced growth inhibition and apoptosis in osteoblastic MC3T3‑E1 cells

Authors:
- Sibo Li
- Haitao Jiang
- Xiaohua Gu
View Affiliations

Affiliations: Department of Orthopedics and Traumatology, The Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai 200137, P.R. China
Published online on: May 18, 2018 https://doi.org/10.3892/etm.2018.6199
Pages: 643-648

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Glucocorticoids (GCs) are widely used to treat chronic diseases. Prolonged and/or overdose administration of GCs has many side‑effects to human health including GC‑induced osteoporosis (GIOP). In this investigation, the objective was to assess the influence that echinacoside (ECH) exerts upon dexamethasone‑treated murine osteoblastic MC3T3‑E1 cells. We found that ECH (5, 10, 20 and 40 mg/l) inhibited dexamethasone (1,000 nM)‑suppressed cell viability as demonstrated by Cell Counting Kit‑8 (CCK‑8) assay. The dose of 10 mg/l was selected for the following experiments because this dose had a better effect than the dose of 5 mg/l, and the doses >10 mg/l had a similar effect as this dose. ECH (10 mg/l) or pifithrin‑α (PFT‑α) (a p53 inhibitor, 20 µM) suppressed dexamethasone‑induced MC3T3‑E1 apoptosis as illustrated by Annexin V/propidium iodide (PI) double‑labeling flow cytometry analysis. ECH or PFT‑α treatment also alleviated dexamethasone's action of inhibiting Bcl‑2 expression as well as dexamethasone's action of stimulating on the expression of p53 and Bax. Moreover, lentivirus mediated‑p53 overexpression reversed the effects of ECH in dexamethasone‑treated MC3T3‑E1 cells, suggesting that ECH induced anti‑apoptotic effects in dexamethasone‑treated osteoblasts via p53‑dependent pathway. In summary, ECH has a protective effect against osteoblastic cell apoptosis induced by dexamethasone, suggesting that ECH may have potentials for clinical application in the treatment of GIOP.

View Figures

View References

1	Buttgereit F, Burmester G-R and Lipworth BJ: Optimised glucocorticoid therapy: The sharpening of an old spear. Lancet. 365:801–803. 2005. View Article : Google Scholar : PubMed/NCBI
2	Schäcke H, Döcke W-D and Asadullah K: Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther. 96:23–43. 2002. View Article : Google Scholar : PubMed/NCBI
3	Fukushima W, Fujioka M, Kubo T, Tamakoshi A, Nagai M and Hirota Y: Nationwide epidemiologic survey of idiopathic osteonecrosis of the femoral head. Clin Orthop Relat Res. 468:2715–2724. 2010. View Article : Google Scholar : PubMed/NCBI
4	Civitelli R and Ziambaras K: Epidemiology of glucocorticoid-induced osteoporosis. J Endocrinol Invest. 31:(Suppl):. 2–6. 2008.PubMed/NCBI
5	Gudbjornsson B, Juliusson UI and Gudjonsson FV: Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice. Ann Rheum Dis. 61:32–36. 2002. View Article : Google Scholar : PubMed/NCBI
6	van Staa TP, Geusens P, Pols HA, de Laet C, Leufkens HG and Cooper C: A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids. QJM. 98:191–198. 2005. View Article : Google Scholar : PubMed/NCBI
7	Rickard DJ, Sullivan TA, Shenker BJ, Leboy PS and Kazhdan I: Induction of rapid osteoblast differentiation in rat bone marrow stromal cell cultures by dexamethasone and BMP-2. Dev Biol. 161:218–228. 1994. View Article : Google Scholar : PubMed/NCBI
8	Li H, Qian W, Weng X, Wu Z, Li H, Zhuang Q, Feng B and Bian Y: Glucocorticoid receptor and sequential P53 activation by dexamethasone mediates apoptosis and cell cycle arrest of osteoblastic MC3T3-E1 cells. PLoS One. 7:e370302012. View Article : Google Scholar : PubMed/NCBI
9	Stoch SA, Saag KG, Greenwald M, Sebba AI, Cohen S, Verbruggen N, Giezek H, West J and Schnitzer TJ: Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: A 12-month randomized, placebo-controlled clinical trial. J Rheumatol. 36:1705–1714. 2009. View Article : Google Scholar : PubMed/NCBI
10	Wallach S, Cohen S, Reid DM, Hughes RA, Hosking DJ, Laan RF, Doherty SM, Maricic M, Rosen C, Brown J, et al: Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int. 67:277–285. 2000. View Article : Google Scholar : PubMed/NCBI
11	Reid DM, Devogelaer J-P, Saag K, Roux C, Lau CS, Reginster JY, Papanastasiou P, Ferreira A, Hartl F, Fashola T, et al: HORIZON investigators: Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): A multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 373:1253–1263. 2009. View Article : Google Scholar : PubMed/NCBI
12	Langdahl BL, Rajzbaum G, Jakob F, Karras D, Ljunggren O, Lems WF, Fahrleitner-Pammer A, Walsh JB, Barker C, Kutahov A, et al: Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-Month data from the European Forsteo Observational Study (EFOS). Calcif Tissue Int. 85:484–493. 2009. View Article : Google Scholar : PubMed/NCBI
13	Saag KG, Zanchetta JR, Devogelaer JP, Adler RA, Eastell R, See K, Krege JH, Krohn K and Warner MR: Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: Thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum. 60:3346–3355. 2009. View Article : Google Scholar : PubMed/NCBI
14	Jia Y, Guan Q, Guo Y and Du C: Echinacoside stimulates cell proliferation and prevents cell apoptosis in intestinal epithelial MODE-K cells by up-regulation of transforming growth factor-β1 expression. J Pharmacol Sci. 118:99–108. 2012. View Article : Google Scholar : PubMed/NCBI
15	Kuang R, Sun Y, Yuan W, Lei L and Zheng X: Protective effects of echinacoside, one of the phenylethanoid glycosides, on H(2)O(2)-induced cytotoxicity in PC12 cells. Planta Med. 75:1499–1504. 2009. View Article : Google Scholar : PubMed/NCBI
16	Kuang R, Sun Y and Zheng X: Suppression of nitric oxide implicated in the protective effect of echinacoside on H₂O₂-induced PC12 cell injury. Nat Prod Commun. 5:571–574. 2010.PubMed/NCBI
17	Deng M, Zhao JY, Tu PF, Jiang Y, Li ZB and Wang YH: Echinacoside rescues the SHSY5Y neuronal cells from TNFalpha-induced apoptosis. Eur J Pharmacol. 505:11–18. 2004. View Article : Google Scholar : PubMed/NCBI
18	Geng X, Tian X, Tu P and Pu X: Neuroprotective effects of echinacoside in the mouse MPTP model of Parkinson's disease. Eur J Pharmacol. 564:66–74. 2007. View Article : Google Scholar : PubMed/NCBI
19	Zhao Q, Gao J, Li W and Cai D: Neurotrophic and neurorescue effects of echinacoside in the subacute MPTP mouse model of Parkinson's disease. Brain Res. 1346:224–236. 2010. View Article : Google Scholar : PubMed/NCBI
20	Zhu M, Lu C and Li W: Transient exposure to echinacoside is sufficient to activate Trk signaling and protect neuronal cells from rotenone. J Neurochem. 124:571–580. 2013. View Article : Google Scholar : PubMed/NCBI
21	Wu Y, Li L, Wen T and Li YQ: Protective effects of echinacoside on carbon tetrachloride-induced hepatotoxicity in rats. Toxicology. 232:50–56. 2007. View Article : Google Scholar : PubMed/NCBI
22	Li X, Gou C, Yang H, Qiu J, Gu T and Wen T: Echinacoside ameliorates D-galactosamine plus lipopolysaccharide-induced acute liver injury in mice via inhibition of apoptosis and inflammation. Scand J Gastroenterol. 49:993–1000. 2014. View Article : Google Scholar : PubMed/NCBI
23	Zhang Y, Xing J, Ai T, Wen T, Guan L and Zhao J: Protection of echinacoside against acute lung injury caused by oleic acid in rats. Free Radic Res. 41:798–805. 2007. View Article : Google Scholar : PubMed/NCBI
24	Li F, Yang Y, Zhu P, Chen W, Qi D, Shi X, Zhang C, Yang Z and Li P: Echinacoside promotes bone regeneration by increasing OPG/RANKL ratio in MC3T3-E1 cells. Fitoterapia. 83:1443–1450. 2012. View Article : Google Scholar : PubMed/NCBI
25	Li F, Yang X, Yang Y, Guo C, Zhang C, Yang Z and Li P: Antiosteoporotic activity of echinacoside in ovariectomized rats. Phytomedicine. 20:549–557. 2013. View Article : Google Scholar : PubMed/NCBI
26	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
27	Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Hoffman B and Reed JC: Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene. 9:1799–1805. 1994.PubMed/NCBI
28	Zhao Q, Yang X, Cai D, Ye L, Hou Y, Zhang L, Cheng J, Shen Y, Wang K and Bai Y: Echinacoside protects against MPP⁺-induced neuronal apoptosis via ros/atf₃/chop pathway regulation. Neurosci Bull. 32:349–362. 2016. View Article : Google Scholar : PubMed/NCBI
29	Chua CC, Chua BH, Chen Z, Landy C and Hamdy RC: Dexamethasone induces caspase activation in murine osteoblastic MC3T3-E1 cells. Biochim Biophys Acta. 1642:79–85. 2003. View Article : Google Scholar : PubMed/NCBI
30	Gross A, McDonnell JM and Korsmeyer SJ: BCL-2 family members and the mitochondria in apoptosis. Genes Dev. 13:1899–1911. 1999. View Article : Google Scholar : PubMed/NCBI